The following clinical trials are currently underway with IM862. Those trials open for enrollment link to the trial protocol. Melanoma Phase II Renal Cell Cancer Phase II Cytran's lead investigational drug, IM862, is available only to patients participating in the Company's clinical trials. IM862 is not yet approved for marketing by the U.S. Food and Drug Administration. Phase I and II clinical studies are customarily designed to determine drug safety, dosing levels, optimum method of administration and to give some indication of efficacy.
Patients receive standardized measurements and are followed to see how well the drug is tolerated.
Phase III studies compare an experimental drug against a placebo or standard treatment. The clinical trials currently underway at Cytran are shown in the table. Not all studies are open for enrollment at this time. Please click here for protocol and enrollment information. Inc. All rights reserved.